HERSHBERG ROBERT sold $748K of ADPT

HERSHBERG ROBERT sold 30,664 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.40 ($24.39–$24.41, $0.75M total) across 2 trades on 2026-08-18.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Aug 20, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The insider sell reduces the director's ownership and may be interpreted as a negative signal, though the amount is modest relative to the company's market cap.

02

Market read

Primary disclosure of insider transaction; modest relevance for short-term traders.

03

What to watch

No disclosed 10b5-1 plan; the director may have personal liquidity needs.

Relevance 5/10Novelty 7/10Timing: post-market 2026-08-18

Background

Form 4 filing by Adaptive Biotechnologies director discloses a $748K share sale.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

Director Robert Hershberg sold 30,664 shares for $748K, reducing his stake to 46,683 shares.

Expected impact

Potential short-term downward pressure on ADPT stock.

Evidence & confidence

The sale size is notable for a director but not material enough to cause large price moves; traders may watch for further insider activity.

Market effects

Minimal impact on biotech sector; insider sell may be viewed as company-specific.

None

Low

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Adaptive Biotechnologies Corp

    US-listed biotech company (ticker ADPT).

  • Robert Hershberg

    Director of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.